Equillium announces oral presentation highlighting positive data from the equate study in acute graft-versus-host disease at the eha2021 virtual congress of the european hematology association

La jolla, calif., may 13, 2021 (globe newswire) -- equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that an abstract highlighting positive data from the equate study of itolizumab in acute graft-versus-host disease (agvhd) has been accepted for oral presentation at eha2021 virtual congress. the annual meeting of the european hematology association will be held virtually june 9 – 17, 2021.
EQ Ratings Summary
EQ Quant Ranking